<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Medidata Solutions, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=23606></link><description><![CDATA[Medidata Solutions, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Fri, 15 May 2026 23:16:32 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2014/10/3554153577_20141031190828_6766956695.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Medidata Selected by ASLAN Pharmaceuticals as Enterprise-Wide Technology Platform for Enhancing Clinical Development]]></title><link>https://www.newswire.co.kr/newsRead.php?no=772069</link><description><![CDATA[NEW YORK--(Business Wire/Korea Newswire)--Medidata  (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has signed an enterprise agreement with ASLAN Pharmaceuticals , an oncology-focused biotechnology company. ASLAN’s adoption of the industry-leading Medidata Clinical Cloud™  supports the company’s strateg...]]></description><pubDate>Fri, 31 Oct 2014 19:25:00 +0900</pubDate></item><item><title><![CDATA[메디데이터, 아슬란제약의 전사적 임상개발 플랫폼으로 선정]]></title><link>https://www.newswire.co.kr/newsRead.php?no=772070</link><description><![CDATA[뉴욕--(Business Wire/뉴스와이어)--메디데이터(Medidata, )(NASDAQ:MDSO)는 오늘 ASLAN Pharmaceuticals과의 엔터프라이즈 계약체결을 공식 발표했다. 아슬란 제약은 글로벌시장 선도 솔루션인 Medidata Clinical Cloud의 도입을 통하여 자사의 사업전략, 즉 임상개발의 품질과 효율을 동시에 높임으로써 인라이센스(in-licensed) 포트폴리오의 가치를 극대화시킨다는 의지를 재확인시켰다.  아슬란 최고운영...]]></description><pubDate>Fri, 31 Oct 2014 19:25:00 +0900</pubDate></item></channel></rss>